Last Published:  07/31/19 10:05:33 AM (Central)
Short Title: CM Validation II
Responsible HRP Element: Space Radiation
Collaborating Org(s):
Other:
Funding Status: Planned-Funded - Task expected to be within budget
Procurement Mechanism(s):
Solicited
Aims:

Studies to validate identified medical countermeasures that address multiple tumor types and multiple risk areas (i.e., cancer, late neurodegeneration, cardiovascular disease) with the following aims:

 

Specific Aims:

  • Aim 1 (Cross Risk): Validate efficacy of candidate countermeasure agents in additional model systems in compliance with FDA animal rules.

  • Aim 2 (Cross Risk): Validate efficacy of candidate countermeasure agents in space relevant environment.

  • Aim 3 (Cross Risk):  Determine minimum dosing (mg/day) requirements for optimum effectiveness.

  • Aim 4 (Cross Risk):  Evaluate any potential antagonistic effects across space radiation risk area endpoints including multiple tumor types

  • Aim 5 (Cross Risk): Evaluate biomarker approaches to assess countermeasure efficacy for surveillance, treatment, and outcome prediction.


Resources (None Listed)
Mappings
RiskRisk of Acute (In-flight) and Late Central Nervous System Effects from Radiation Exposure
You are here!TaskContracted Study CM Validation II (Cross Risk)

RiskRisk of Adverse Cognitive or Behavioral Conditions and Psychiatric Disorders
You are here!TaskContracted Study CM Validation II (Cross Risk)

RiskRisk of Cardiovascular Disease and Other Degenerative Tissue Effects From Radiation Exposure and Secondary Spaceflight Stressors
You are here!TaskContracted Study CM Validation II (Cross Risk)

RiskRisk of Radiation Carcinogenesis
You are here!TaskContracted Study CM Validation II (Cross Risk)